Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-I7 for Elderly Patients with Asymptomatic or Mild COVID-19
NCT04810637Phase 2Unknown
- Sponsor
- Kalbe Genexine Biologics
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efineptakin alfa in coronavirus disease 2019 (COVID-19), sponsored by Kalbe Genexine Biologics. Status: unknown.
02
Drugs
efineptakin alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04810637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810637.